Editor-Curated Robotics Industry Briefing - RobotToday

ROPCA Secures FDA Approval for Autonomous Ultrasound Robot ARTHUR for Rheumatoid Arthritis Diagnosis

Danish medical technology company ROPCA has received FDA 510(k) approval for its autonomous ultrasound robot, ARTHUR, designed for diagnosing rheumatoid arthritis. This innovative system allows patients to place their hands on a designated area while the robot, equipped with AI software DIANA, performs standardized ultrasound scans without the need for a physician's intervention. The significance of this approval lies in addressing the shortage of rheumatology specialists in the U.S., where 72% of counties lack access to such experts. With ARTHUR's ability to conduct efficient and repeatable joint ultrasound assessments, it aims to enhance the accessibility of objective imaging and improve clinical capabilities, as noted by Dr. Matthew J. Koster from the Mayo Clinic. Looking ahead, ROPCA's ARTHUR could revolutionize the diagnostic process for rheumatoid arthritis, potentially reducing the lengthy wait times patients currently face for joint ultrasound evaluations. No further timeline was disclosed at the time of publication.